Skip to main content
. 2014 Jul 29;16(4):R160. doi: 10.1186/ar4675

Figure 1.

Figure 1

Clinical response to treatment is independent of trough serum adalimumab levels. Trough serum adalimumab levels at the end of treatment (2 weeks after the last injection) were not different between patients treated with 12 or 24 weeks of adalimumab (A) or between responders and nonresponders (B) Median (interquartile range). Also, there was no correlation between these drug levels and clinical disease activity parameters such as patient’s global assessment of disease activity measured on a 100-mm visual analogue scale (VAS) (C) or C-reactive protein (CRP) level (D).